Cargando…

Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells

The pre-metastatic microenvironment consists of pro-metastatic and anti-metastatic immune cells in the early stages of cancer, when the primary tumor begins to proliferate. Redundantly, pro-inflammatory immune cells predominated during tumor growth. Although it is well known that pre-metastatic inna...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Chenxue, Kato, Masayoshi, Tomita, Takeshi, Han, Yibing, Hiratsuka, Sachie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995318/
https://www.ncbi.nlm.nih.gov/pubmed/36890150
http://dx.doi.org/10.1038/s41598-023-30476-4
_version_ 1784902796444696576
author Yin, Chenxue
Kato, Masayoshi
Tomita, Takeshi
Han, Yibing
Hiratsuka, Sachie
author_facet Yin, Chenxue
Kato, Masayoshi
Tomita, Takeshi
Han, Yibing
Hiratsuka, Sachie
author_sort Yin, Chenxue
collection PubMed
description The pre-metastatic microenvironment consists of pro-metastatic and anti-metastatic immune cells in the early stages of cancer, when the primary tumor begins to proliferate. Redundantly, pro-inflammatory immune cells predominated during tumor growth. Although it is well known that pre-metastatic innate immune cells and immune cells fighting primary tumor cells become exhausted, the mechanism by which this occurs is unknown. We discovered that anti-metastatic NK cells were mobilized from the liver to the lung during primary tumor progression and that the transcription factor CEBPδ, which was upregulated in a tumor-stimulated liver environment, inhibited NK cell attachment to the fibrinogen-rich bed in pulmonary vessels and sensitization to the environmental mRNA activator. CEBPδ-siRNA treated anti-metastatic NK cells regenerated the binding proteins that support sitting in fibrinogen-rich soil, such as vitronectin and thrombospondin, increasing fibrinogen attachment. Furthermore, CEBPδ knockdown restored an RNA-binding protein, ZC3H12D, which captured extracellular mRNA to increase tumoricidal activity. Refreshed NK cells using CEBPδ-siRNA with anti-metastatic abilities would work at metastatic risk areas in the pre-metastatic phase, resulting in a reduction in lung metastasis. Furthermore, tissue-specific siRNA-based therapy in lymphocyte exhaustion may be beneficial in the treatment of early metastases.
format Online
Article
Text
id pubmed-9995318
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99953182023-03-10 Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells Yin, Chenxue Kato, Masayoshi Tomita, Takeshi Han, Yibing Hiratsuka, Sachie Sci Rep Article The pre-metastatic microenvironment consists of pro-metastatic and anti-metastatic immune cells in the early stages of cancer, when the primary tumor begins to proliferate. Redundantly, pro-inflammatory immune cells predominated during tumor growth. Although it is well known that pre-metastatic innate immune cells and immune cells fighting primary tumor cells become exhausted, the mechanism by which this occurs is unknown. We discovered that anti-metastatic NK cells were mobilized from the liver to the lung during primary tumor progression and that the transcription factor CEBPδ, which was upregulated in a tumor-stimulated liver environment, inhibited NK cell attachment to the fibrinogen-rich bed in pulmonary vessels and sensitization to the environmental mRNA activator. CEBPδ-siRNA treated anti-metastatic NK cells regenerated the binding proteins that support sitting in fibrinogen-rich soil, such as vitronectin and thrombospondin, increasing fibrinogen attachment. Furthermore, CEBPδ knockdown restored an RNA-binding protein, ZC3H12D, which captured extracellular mRNA to increase tumoricidal activity. Refreshed NK cells using CEBPδ-siRNA with anti-metastatic abilities would work at metastatic risk areas in the pre-metastatic phase, resulting in a reduction in lung metastasis. Furthermore, tissue-specific siRNA-based therapy in lymphocyte exhaustion may be beneficial in the treatment of early metastases. Nature Publishing Group UK 2023-03-08 /pmc/articles/PMC9995318/ /pubmed/36890150 http://dx.doi.org/10.1038/s41598-023-30476-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yin, Chenxue
Kato, Masayoshi
Tomita, Takeshi
Han, Yibing
Hiratsuka, Sachie
Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells
title Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells
title_full Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells
title_fullStr Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells
title_full_unstemmed Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells
title_short Suppression of CEBPδ recovers exhaustion in anti-metastatic immune cells
title_sort suppression of cebpδ recovers exhaustion in anti-metastatic immune cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995318/
https://www.ncbi.nlm.nih.gov/pubmed/36890150
http://dx.doi.org/10.1038/s41598-023-30476-4
work_keys_str_mv AT yinchenxue suppressionofcebpdrecoversexhaustioninantimetastaticimmunecells
AT katomasayoshi suppressionofcebpdrecoversexhaustioninantimetastaticimmunecells
AT tomitatakeshi suppressionofcebpdrecoversexhaustioninantimetastaticimmunecells
AT hanyibing suppressionofcebpdrecoversexhaustioninantimetastaticimmunecells
AT hiratsukasachie suppressionofcebpdrecoversexhaustioninantimetastaticimmunecells